In addition, due to the success of treatment of BC patients in the UK, most of the patients used for this study have survived > 12 months post-surgery without progression, making comparisons of PDE responses to patient outcomes difficult, unlike the case with NSCLC-PDEs20. The gene discussed is ALDH7A1; the disease is breast cancer.